SBI’s structural I.T. and drug discovery products and services are designed to: 1) speed the drug discovery and optimization processes; 2) greatly increase efficiency in time and cost for both high throughput screening and virtual screening; 3) foster improved performance (e.g., selectivity, toxicity, efficacy) toward generation of “best-in-class” and “next generation” drugs; and 4) maximize the intellectual property position (e.g. composition-of-matter protection for multiple drug-like chemical scaffolds), and greatly increase the likelihood of ultimate technical and marketing success.

SBI’s ProMax database is comprised of thousands of pharmaceutically relevant protein structures in more than 450 distinct protein structural families. ProMax™ addresses the need for immediate and broad access to high quality protein structure information across many life-science applications – both qualitative and quantitative – to speed the drug design or discovery and optimization processes, enhance drug selectivity, select optimal counter screens and animal disease models, improve compound screening performance, conduct virtual screening, and in general increase experimental efficiency, reduce cost, and increase the probability of success.™

Our Variome database modules consist of large-scale drug target specific collections of high-quality protein structures generated from the genetic sequence variants (polymorphisms) from tens of thousands of individuals. Variome™ modules provide a definitive understanding of the shape repertoire of structural variations of drug targets within the potential patient population, which is critical to optimal drug design.™

SBI’s DynaPharm technology permits the generation of active initial drug lead compounds from a drug target sequence, with typical “hit rates” of 10%, (in marked contrast to 0.01% to 0.001% for typical high-throughput screening). The process is quick (i.e., 60-120 days), applicable simultaneously to numerous targets, and well suited to handle the challenge posed by the advent of thousands of potential new drug targets emerging from genomics efforts.^®

Our products are designed to serve researchers across many scientific disciplines, and can be used to your advantage on an enterprise-wide, or on a project-by-project basis.